期刊
PLOS MEDICINE
卷 9, 期 10, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pmed.1001326
关键词
-
资金
- Innovative Medicine Initiative Joint Undertaking (IMI-JU) [115008]
- European Union's Seventh Framework Programme
- European Commission
- EC [LSHB-CT-2003-503428]
- GlaxoSmithKline [G0701420]
- UK National Institute for Health Research of the Department of Health
- UK Medical Research Council
- Mental Health Research Network
- Wyeth-Lederle
- Bristol-Myers Squibb
- Sanofi Aventis
- Canada Research Chair program
- NIMH [N01MH90003, MH072802]
- Bristol-Myers-Squibb
- Lundbeck
- Lilly
- Medical Research Council (UK)
- Wellcome Trust
- National Institutes of Medicine (USA)
- European Union
- Roche Molecular Systems
- Roche Diagnostics
- Johnson Johnson
- Otsuka Pharmaceuticals Limited
- Johnson AMP
- Johnson Pharmaceutical Research and Development
- AstraZeneca
- MRC [G0200243, G0701420] Funding Source: UKRI
- Medical Research Council [G0701420, G0200243, G9817803B, G0801418B] Funding Source: researchfish
Background: It has been suggested that outcomes of antidepressant treatment for major depressive disorder could be significantly improved if treatment choice is informed by genetic data. This study aims to test the hypothesis that common genetic variants can predict response to antidepressants in a clinically meaningful way. Methods and Findings: The NEWMEDS consortium, an academia-industry partnership, assembled a database of over 2,000 European-ancestry individuals with major depressive disorder, prospectively measured treatment outcomes with serotonin reuptake inhibiting or noradrenaline reuptake inhibiting antidepressants and available genetic samples from five studies (three randomized controlled trials, one part-randomized controlled trial, and one treatment cohort study). After quality control, a dataset of 1,790 individuals with high-quality genome-wide genotyping provided adequate power to test the hypotheses that antidepressant response or a clinically significant differential response to the two classes of antidepressants could be predicted from a single common genetic polymorphism. None of the more than half million genetic markers significantly predicted response to antidepressants overall, serotonin reuptake inhibitors, or noradrenaline reuptake inhibitors, or differential response to the two types of antidepressants (genome-wide significance p<5x10(-8)). No biological pathways were significantly overrepresented in the results. No significant associations (genome-wide significance p, 5610 28) were detected in a meta-analysis of NEWMEDS and another large sample (STAR*D), with 2,897 individuals in total. Polygenic scoring found no convergence among multiple associations in NEWMEDS and STAR* D. Conclusions: No single common genetic variant was associated with antidepressant response at a clinically relevant level in a European-ancestry cohort. Effects specific to particular antidepressant drugs could not be investigated in the current study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据